Cashu FinanceCashu Finance
  • Terminal
  • Pulse
  • Spotlight
  • News
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. OTC
  4. NVSEF

Market Cap: $295.56B

NA

Novartis AG

NVSEF
OTC (Other OTC)USD
Invest in NVSEF
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksScreenersAboutAuthorsAdvertisersBrokersConferencesContact

Legal

Terms of ServicePrivacy PolicyEditorial PolicyCorrections Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

Novartis AG Financials

Profitability, balance-sheet strength and valuation from the latest reported results (trailing twelve months).

Financial Health Scores

Piotroski F-Score

7/9 · Strong

Nine pass/fail checks on profitability, leverage, liquidity and efficiency. 7–9 is strong, 0–3 is weak.

Altman Z-Score

3.67
Distress <1.8Grey 1.8–3Safe >3

Safe zone: low near-term bankruptcy risk.

From Revenue to Profit

How much of each dollar of sales is kept at each stage (last 12 months).

  • Revenue$54.5B100.0%
  • Gross Profit$40.5B74.3%
  • EBITDA$22.29B40.9%
  • Operating Profit (EBIT)$17.04B31.3%
  • Net Profit$9.84B18.1%

Balance Sheet Snapshot

Total assets of $117.01B, funded by:

Liabilities
$79.49B(68%)
Shareholders' equity
$37.52B
Debt / Equity
1.30x
Current Ratio
0.88x

Short-term liabilities exceed short-term assets.

Returns on Capital

How well management turns capital into profit. Above 10–15% is generally considered strong.

  • Return on Equity24.2%

    Profit generated per dollar of shareholders' money.

  • Return on Assets8.4%

    Profit generated per dollar of assets owned.

  • Return on Invested Capital14.0%

    Profit generated on debt and equity invested in the business.

  • Return on Capital Employed19.7%

    Operating profit per dollar of long-term capital.

Valuation at a Glance

Lower multiples can mean cheaper shares, or a market expecting weaker results.

Price / Earnings
30.76x

What investors pay for each dollar of yearly profit.

Price / Book
8.11x

Share price vs net assets per share. Under 1x = below book value.

Price / Sales
5.50x

Market cap vs yearly revenue.

EV / EBITDA
15.09x

Whole-business value (incl. debt) vs operating cash earnings.

Price / Free Cash Flow
19.69x

Market cap vs cash left after capital spending.

PEG Ratio
n/m

P/E adjusted for earnings growth. Around 1x is often seen as fair.

All Key Metrics

Every trailing-twelve-month ratio behind the charts above, grouped by topic. Pick a category to browse.

Profitability

How much of each dollar of revenue turns into profit at each stage, over the last 12 months.

Gross Profit Margin
74.30%
EBITDA Margin
40.89%
EBIT Margin
31.26%
Pre-tax Margin
22.77%
Net Profit Margin
18.06%
Earnings Yield
3.30%

Valuation Multiples

How the share price compares with earnings, sales, book value and cash flow. Lower multiples can mean cheaper shares, or weaker prospects.

Price / Book
8.11
Price / Sales
5.50
Price / Earnings
30.76
PEG
-1.05
Forward PEG
86.49
EV / Sales
6.17
EV / EBITDA
15.09
EV / Operating Cash Flow
19.94
EV / Free Cash Flow
22.12
Price / Free Cash Flow
19.69
Price / Operating Cash Flow
17.83

Cash Flow & Capital

How much cash the business generates, how much it reinvests, and what it returns to shareholders.

Free Cash Flow / Share
$8.09
Operating Cash Flow / Share
$8.97
Free Cash Flow Yield
5.12%
Capex / Revenue
3.04%
Capex / Operating Cash Flow
9.82%
Capex / Depreciation
0.32
Stock Compensation / Revenue
0.00%
Dividend Payout Ratio
89.56%
Dividend Yield
2.76%

Liquidity & Leverage

Whether the company can cover its short-term bills and how heavily it relies on debt.

Current Ratio
0.88
Quick Ratio
0.70
Cash Ratio
0.27
Debt / Assets
0.41
Debt / Capital
0.56
Debt / Equity
1.30
Long-Term Debt / Capital
0.50
Debt / Market Cap
15.51%
Net Debt / EBITDA
1.76
Solvency Ratio
0.19
Financial Leverage
3.15

Efficiency & Working Capital

How quickly the company turns assets, inventory and receivables into sales and cash.

Asset Turnover
0.47
Fixed Asset Turnover
4.46
Inventory Turnover
2.30
Receivables Turnover
5.49
Payables Turnover
3.31
Days Sales Outstanding
66.47
Days Inventory Outstanding
158.47
Days Payables Outstanding
110.16
Operating Cycle
224.94
Cash Conversion Cycle
114.78
Working Capital Turnover
-13.40

Returns & Quality

How efficiently management turns shareholders' money and company assets into profit.

Return on Equity
24.24%
Return on Assets
8.43%
Return on Invested Capital
13.96%
ROCE
19.70%
Return on Tangible Assets
19.70%
Operating Return on Assets
13.95%
Income Quality
1.71
Tax Burden
0.79
Interest Burden
0.73

Balance Sheet & Intrinsic Metrics

What the company owns and owes, and asset-based value estimates per share.

Enterprise Value
$339.21B
Invested Capital
$75.83B
Working Capital
$-3.79B
Tangible Asset Value
$-29.57B
Net Current Asset Value
$-51.07B
Graham Number
$48.2
Graham Net-Net
-$31.83
Book Value / Share
$19.9
Tangible Book Value / Share
-$15.6
Cash / Share
$4.75

Financial Health Scores

Composite scores and the latest reported totals behind them.

Piotroski Score
7
Altman Z-Score
3.67
Revenue
$54.5B
EBIT
$17.45B
Market Cap
$306.18B
Working Capital
$-3.77B
Retained Earnings
$36.5B
Total Assets
$117.01B
Total Liabilities
$79.49B